Latest news with #Brukinsa
Glasgow Times
9 hours ago
- Health
- Glasgow Times
Three new cancer drugs approved for use for NHS Scotland
The Scottish Medicines Consortium (SMC) approved the drug brentuximab vedotin, also known as Adcetris, which can be used together with chemotherapy as a first-line treatment for adult patients with advanced Hodgkin lymphoma – an uncommon cancer that develops in the lymphatic system. (Image: Image from PA) SMC vice chair Graeme Bryson said the treatment could 'help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse'. Meanwhile, zanubrutinib, also known as Brukinsa, was accepted to treat adults with mantle cell lymphoma – a rare type of the blood cancer non-Hodgkin lymphoma. The SMC has also approved the drug ripretinib – also known as Qinlock – to treat adults with advanced gastrointestinal stromal tumours, which are a rare type of cancer of the digestive system. In addition to these drugs it has agreed the NHS can use mirikizumab, also known as Omvoh, for adults with Crohn's disease, a lifelong condition which is a chronic inflammatory bowel disease. READ NEXT: Rock band to play huge headline show in Glasgow Graeme Bryson said: 'The committee is pleased to be able to accept these new medicines for use by NHS Scotland. 'Brentuximab vedotin, used together with chemotherapy, could help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse. 'Ripretinib provides a fourth-line treatment for advanced gastro-intestinal stromal tumours where currently there is no standard treatment available. 'Zanubrutinib offers an additional oral targeted treatment option for patients with mantle cell lymphoma who have already received one or more lines of treatment. 'Mirikizumab offers an additional treatment option for people with moderate to severe Crohn's disease whose disease is not controlled on standard or biologic treatment.' READ NEXT: Two teens nicked after 'DPD van chased' through streets by cops However, the Scottish Medicines Consortium (SMC) said it could not approve a new treatment for patients with the lung condition chronic obstructive pulmonary disease (COPD) because of a lack of evidence around its cost-effectiveness. It also rejected the drug dupilumab, also known as Dupixent, as a treatment on the NHS for adults with COPD that is controlled on current standard treatments. Bryson said: 'The committee was unable to accept dupilumab for treating patients with COPD as the company's evidence around the cost-effectiveness of the treatment was not sufficient. We would welcome a resubmission from the company.' Joseph Carter, head of the charity Asthma + Lung UK Scotland, added: 'If the cost effectiveness of dupilumab for use by NHS Scotland can be improved, we are hopeful that the Scottish Medicines Consortium will revisit its decision. 'With an estimated 241,000 people living with COPD in Scotland, there is hope that this drug could help guide research for other targeted therapies. 'More lung research is desperately needed to enable a breakthrough to help better control or even cure COPD.'
STV News
14 hours ago
- Health
- STV News
Three new cancer drugs approved for use for NHS Scotland
Three new treatments for cancer have been approved for use by the NHS in Scotland. The Scottish Medicines Consortium (SMC) however said it could not approve a new treatment for patients with the lung condition chronic obstructive pulmonary disease (COPD) because of a lack of evidence around its cost-effectiveness. However, the SMC did approve the drug brentuximab vedotin, also known as Adcetris, to be used together with chemotherapy as a first-line treatment for adult patients with advanced Hodgkin lymphoma – an uncommon cancer that develops in the lymphatic system. SMC vice chair Graeme Bryson said the treatment could 'help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse'. Meanwhile, zanubrutinib, also known as Brukinsa, was accepted to treat adults with mantle cell lymphoma – a rare type of the blood cancer non-Hodgkin lymphoma. The SMC has also approved the drug ripretinib – also known as Qinlock – to treat adults with advanced gastrointestinal stromal tumours, which are a rare type of cancer of the digestive system. In addition to these drugs it has agreed the NHS can use mirikizumab, also known as Omvoh, for adults with Crohn's disease, a lifelong condition which is a chronic inflammatory bowel disease. However, the SMC rejected the drug dupilumab, also known as Dupixent, as a treatment on the NHS for adults with COPD that is controlled on current standard treatments. Mr Bryson said: 'The committee is pleased to be able to accept these new medicines for use by NHS Scotland. 'Brentuximab vedotin, used together with chemotherapy, could help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse. 'Ripretinib provides a fourth-line treatment for advanced gastro-intestinal stromal tumours where currently there is no standard treatment available. 'Zanubrutinib offers an additional oral targeted treatment option for patients with mantle cell lymphoma who have already received one or more lines of treatment. 'Mirikizumab offers an additional treatment option for people with moderate to severe Crohn's disease whose disease is not controlled on standard or biologic treatment.' However he added: 'The committee was unable to accept dupilumab for treating patients with COPD as the company's evidence around the cost-effectiveness of the treatment was not sufficient. We would welcome a resubmission from the company.' Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
Daily Record
15 hours ago
- Health
- Daily Record
Three new cancer drugs approved for use for NHS Scotland
The drugs have been approved for use by the NHS in Scotland. Three new treatments for cancer have been approved for use by the NHS in Scotland. The Scottish Medicines Consortium (SMC) however said it could not approve a new treatment for patients with the lung condition chronic obstructive pulmonary disease (COPD) because of a lack of evidence around its cost-effectiveness. However, the SMC did approve the drug brentuximab vedotin, also known as Adcetris, to be used together with chemotherapy as a first-line treatment for adult patients with advanced Hodgkin lymphoma – an uncommon cancer that develops in the lymphatic system. SMC vice chair Graeme Bryson said the treatment could 'help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse'. Ex-gangster Ian 'Blink' MacDonald turns back on underworld after pals all die from drugs and shootings Dad of schoolgirl slain in Dunblane massacre warns gun licensing reform does not go far enough Meanwhile, zanubrutinib, also known as Brukinsa, was accepted to treat adults with mantle cell lymphoma – a rare type of the blood cancer non-Hodgkin lymphoma. The SMC has also approved the drug ripretinib – also known as Qinlock – to treat adults with advanced gastrointestinal stromal tumours, which are a rare type of cancer of the digestive system. In addition to these drugs it has agreed the NHS can use mirikizumab, also known as Omvoh, for adults with Crohn's disease, a lifelong condition which is a chronic inflammatory bowel disease. However, the SMC rejected the drug dupilumab, also known as Dupixent, as a treatment on the NHS for adults with COPD that is controlled on current standard treatments. Join the Daily Record WhatsApp community! Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile, select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'. If you're curious, you can read our Privacy Notice. NHS Scotland. ' Brentuximab vedotin, used together with chemotherapy, could help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse. 'Ripretinib provides a fourth-line treatment for advanced gastro-intestinal stromal tumours where currently there is no standard treatment available. 'Zanubrutinib offers an additional oral targeted treatment option for patients with mantle cell lymphoma who have already received one or more lines of treatment. 'Mirikizumab offers an additional treatment option for people with moderate to severe Crohn's disease whose disease is not controlled on standard or biologic treatment.' However he added: 'The committee was unable to accept dupilumab for treating patients with COPD as the company's evidence around the cost-effectiveness of the treatment was not sufficient. We would welcome a resubmission from the company.'
The Herald Scotland
15 hours ago
- Health
- The Herald Scotland
Three new cancer drugs approved for use for NHS Scotland
However, the SMC did approve the drug brentuximab vedotin, also known as Adcetris, to be used together with chemotherapy as a first-line treatment for adult patients with advanced Hodgkin lymphoma – an uncommon cancer that develops in the lymphatic system. SMC vice chair Graeme Bryson said the treatment could 'help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse'. Meanwhile, zanubrutinib, also known as Brukinsa, was accepted to treat adults with mantle cell lymphoma – a rare type of the blood cancer non-Hodgkin lymphoma. READ MORE: The SMC has also approved the drug ripretinib – also known as Qinlock – to treat adults with advanced gastrointestinal stromal tumours, which are a rare type of cancer of the digestive system. In addition to these drugs it has agreed the NHS can use mirikizumab, also known as Omvoh, for adults with Crohn's disease, a lifelong condition which is a chronic inflammatory bowel disease. However, the SMC rejected the drug dupilumab, also known as Dupixent, as a treatment on the NHS for adults with COPD that is controlled on current standard treatments. Mr Bryson said: 'The committee is pleased to be able to accept these new medicines for use by NHS Scotland. 'Brentuximab vedotin, used together with chemotherapy, could help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse. 'Ripretinib provides a fourth-line treatment for advanced gastro-intestinal stromal tumours where currently there is no standard treatment available. 'Zanubrutinib offers an additional oral targeted treatment option for patients with mantle cell lymphoma who have already received one or more lines of treatment. 'Mirikizumab offers an additional treatment option for people with moderate to severe Crohn's disease whose disease is not controlled on standard or biologic treatment.' However he added: 'The committee was unable to accept dupilumab for treating patients with COPD as the company's evidence around the cost-effectiveness of the treatment was not sufficient. We would welcome a resubmission from the company.'
&w=3840&q=100)
Business Standard
10-06-2025
- Business
- Business Standard
Glenmark Pharma rises 2% as company to launch blood cancer treatment drug
Glenmark Pharma share price rose 1.7 per cent in trade on Tuesday, June 10, 2025, logging an intraday high at ₹1,626.6 per share on BSE. At 10:30 AM, Glenmark Pharma shares were trading 1.56 per cent higher at ₹1,623.35 per share on the BSE. In comparison, the BSE Sensex was up 0.05 per cent at 82,482.52. The company's market capitalisation stood at ₹45,811.07 crore. Its 52-week high was at ₹1,830.05 per share and 52-week low was at ₹1,176 per share. In the past one year, Glenmark shares have gained 33 per cent as compared to Sensex's rise of around 8 per cent. What is boosting rally in Glenmark Pharma shares? The stock gained after the company announced the upcoming launch of zanubrutinib, under the brand name Brukinsa in India. Brukinsa, developed by global oncology company BeOne Medicines (formerly BeiGene), is an orally available Bruton's tyrosine kinase (BTK) inhibitor designed to treat multiple types of B-cell blood cancers. It is the first and only BTK inhibitor approved in India for five types of B-cell malignancies. According to the filing, Brukinsa has already been approved in more than 70 countries, with clinical efficacy demonstrated through trials such as ALPINE, ASPEN and SEQUOIA. Its entry into the Indian market addresses a critical need for new and effective blood cancer treatments. The drug offers a unique pharmacological profile with high response rates and durable disease control across multiple B-cell malignancies. It allows a flexible dosing schedule—once or twice daily—tailored to patient needs. In the ALPINE trial for relapsed or refractory chronic lymphocytic leukaemia (CLL), Brukinsa showed a lower incidence of serious cardiac side effects compared to ibrutinib, a widely used targeted therapy. Fewer patients discontinued Brukinsa due to heart-related complications. About Glenmark Pharmaceuticals Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. About BeOne Medicines BeOne Medicines, formerly known as BeiGene, is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide.
